| 2023 | Oral Porphyromonas gingivalis infection affects intestinal microbiota and promotes atherosclerosis | JOURNAL OF CLINICAL PERIODONTOLOGY |
| 2003 | Oral Tegafur-uracil Plus Folinic Acid versus Intravenous 5-fluorouracil Plus Folinic Acid as Adjuvant Chemotherapy of Colon Cancer
| YONSEI MEDICAL JOURNAL |
| 2022 | ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib | ANNALS OF ONCOLOGY |
| 2013 | Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma
| ONCOTARGETS AND THERAPY |
| 2023 | Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON
| CANCER DISCOVERY |
| 2020 | Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
| CANCER RESEARCH AND TREATMENT |
| 2018 | Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2017 | Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial | JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Osimertinib Plus Savolitinib in Patients With EGFR Mutation-Positive, MET-amplified, Non-Small-Cell Lung Cancer After Progression on EGFR Tyrosine Kinase Inhibitors: Interim Results From a Multicentre, Open-Label, Phase 1b Study | LANCET ONCOLOGY |
| 2019 | Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset | JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I | MOLECULAR CANCER THERAPEUTICS |
| 2015 | Osteitis fibrosa cystica in primary hyperparathyroidism
| QJM-AN INTERNATIONAL JOURNAL OF MEDICINE |
| 2012 | Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells
| BLOOD |
| 2020 | Osteoclast-associated receptor blockade prevents articular cartilage destruction via chondrocyte apoptosis regulation
| NATURE COMMUNICATIONS |
| 2011 | Osteolytic mandible presenting as an initial manifestation of an adult acute lymphoblastic leukaemia | INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY |
| 2010 | Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases | OSTEOPOROSIS INTERNATIONAL |
| 2008 | Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis
| RHEUMATOLOGY |
| 2017 | Osteosarcoma in a Patient With Pseudohypoparathyroidism Type 1b Due to Paternal Uniparental Disomy of Chromosome 20q | JOURNAL OF BONE AND MINERAL RESEARCH |
